Clinical Use and Patentability of Cord Blood

Author(s): Turker Cavusoglu*, Kubilay Dogan Kilic, Gurkan Yigitturk, Canberk Tomruk, Mehmet Turgut, Yigit Uyanikgil

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 11 , Issue 1 , 2017


Abstract:

Background: The blood in the umbilical cord that provides the connection between mother and fetus during pregnancy is called cord blood. The blood of umbilical cord which is usually got rid of following birth, is a very rich stem cell source.

Objective: Cord blood collection gives no harm to the mother and baby. Besides, its allogeneic and autologous usage, the most important disadvantage is that the number of cells is insufficient in adults.

Conclusion: Today, it is predominantly used for therapeutic purposes for many diseases. The aim of this review is giving a detailed information about groups of stem cells in cord blood and determining the point of clinical use.

Keywords: Clinical use, cord blood, stem cell, umblical cord blood, patent, haematology, haemopoetic diseases.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 1
Year: 2017
Published on: 14 March, 2018
Page: [13 - 21]
Pages: 9
DOI: 10.2174/1872214812666180314121241
Price: $65

Article Metrics

PDF: 246
HTML: 3